Although AGO2 gene expression held prognostic relevance in cholangiocarcinoma (HR: 0.38, P = 0.044), renal cell carcinoma (HR: 2.15, P = 0.016), mesothelioma (HR: 2.36, P = 0.00053), sarcoma (HR: 1.71, P = 0.0092), and endometrial carcinoma (HR: 1.83, P = 0.0052), in none of these other cancer types did AGO2 demonstrate such a significant prognostic impact as in ACC (Supplementary Table 1). Here, AGO2 is linked to sarcoma.